Oct 7 (Reuters) – SeaStar Medical Holding Corp: * FDA GRANTS SEASTAR MEDICAL BREAKTHROUGH DEVICE DESIGNATION FOR ITS SCD THERAPY FOR THE TREATMENT OF HYPERINFLAMMATION IN ADULT PATIENTS WITH SEPSIS OR
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: INTERVIEW WITH GARY LINEKER / B-ROLL OF CRISTIANO RONALDO / B-ROLL OF MAN…
By Giulio Piovaccari TURIN, Italy, Oct 7 (Reuters) - When John Elkann first started thinking seriously…
(Adds: Wittington Investments, JAVYS Updates: Rosatom) Oct 7 (Reuters) - The following bids, mergers, acquisitions…
By Krystal Hu Oct 7 (Reuters) - The US government and tech heavyweights Meta Platforms…
(Adds details on deal and background from paragraph 2) Oct 7(Reuters) - Canada's Weston family…
VIDEO SHOWS: INTERVIEW WITH SARA PRICE / SARA PRICE AND RICKY BRABEC LEADING A MEDIA…